445-04-5Relevant articles and documents
The aqueous photolysis of TFM and related trifluoromethylphenols. An alternate source of trifluoroacetic acid in the environment
Ellis, David A.,Mabury, Scott A.
, p. 632 - 637 (2000)
The lampricide 3-trifluoromethyl-4-nitrophenol (TFM) is added annually to the Great Lakes (approximately 50 000 kg/y), with treatment concentrations varying from 1 to 14 mg/L at source. TFM was shown to undergo photohydrolytic degradation, at 365 nm and u
New clicked full agonists of the estrogen receptor β
Demkowicz, Sebastian,Filipiak, Kamila,Maslyk, MacIej,Ciepielski, Jakub,De Pascual-Teresa, Sonia,Martin-Santamaria, Sonsoles,De Pascual-Teresa, Beatriz,Ramos, Ana
, p. 3697 - 3706 (2013/04/10)
A click chemistry approach was used to synthesize a series of 1,4-diaryl-substituted 1,2,3-triazoles designed to behave as estrogen receptor (ER) ligands. We studied their affinities for both receptors α and β, their agonist activities in a cell-based luciferase reporter assay and their effect on the proliferation of the hormone-dependent MCF-7 cell line. We found two compounds (3a and 3c) that behave as selective full agonists for ERβ at a 20 μM concentration, and one of them (3c) showed no proliferative effect on MCF-7 cells.
Novel potent BRAF inhibitors: Toward 1 nM compounds through optimization of the central phenyl ring
Ménard, Delphine,Niculescu-Duvaz, Ion,Dijkstra, Harmen P.,Niculescu-Duvaz, Dan,Suijkerbuijk, Bart M. J. M.,Zambon, Alfonso,Nourry, Arnaud,Roman, Esteban,Davies, Lawrence,Manne, Helen A.,Friedlos, Frank,Kirk, Ruth,Whittaker, Steven,Gill, Adrian,Taylor, Richard D.,Marais, Richard,Springer, Caroline J.
supporting information; experimental part, p. 3881 - 3891 (2010/02/17)
BRAF, a serine/threonine specific protein kinase that is part of the MAPK pathway and acts as a downstream effector of RAS, is a potential therapeutic target in melanoma. We have developed a series of small-molecule BRAF inhibitors based on a 1H-imidazo[4,5-b]pyridine-2(3H)-one scaffold (ring A) as the hinge binding moiety and a number of substituted phenyl rings C that interact with the allosteric binding site. The introduction of various groups on the central phenyl ring B combined with appropriate A- and C-ring modifications afford very potent compounds that inhibit V600EBRAF kinase activity in vitro and oncogenic BRAF signaling in melanoma cells. Substitution on the central phenyl ring of a 3-fluoro, a naphthyl, or a 3-thiomethyl group improves activity to yield compounds with an IC50 of 1 nM for purified V 600EBRAF and nanomolar activity in cells.
